ArticlePhysiological research2026
RPS3 Aggravates Sepsis-Induced Acute Kidney Injury Through Activating NF-kappaB Mediated Renal Inflammatory Responses.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive inflammatory responses represent one of the primary causes of sepsis- associated acute kidney injury (S-AKI). The activation of the nuclear factor-kappa B (NF-kappaB) signaling pathway plays a critical role in the pathogenesis and progression of S-AKI. Previous studies have demonstrated that ribosomal protein S3 (RPS3) serves as a pivotal regulator of the NF-kappaB pathway; however, its specific biological functions in the context of S-AKI remain to be fully elucidated. This study aims to elucidate the regulatory mechanisms of RPS3 in S-AKI-associated inflammation and to explore the underlying molecular pathways. First, we conducted an analysis of RPS3 level in urine and TNF-alpha level in serum from S-AKI patients recruited at our hospital. Second, we established a murine model of S-AKI by intraperitoneal injection of LPS, followed by the evaluation of renal function, inflammatory response, RPS3 expression, and NF-kappaB activation in renal tissues. Finally, we explored the regulatory role and underlying mechanism of RPS3 in the LPS-induced inflammatory response in HK-2 cells through RPS3 knockdown and the introduction of an NF-kappaB agonist. The results demonstrated that urinary RPS3 and serum TNF-alpha levels were significantly elevated in patients with S-AKI, with a positive correlation observed between these two parameters. In LPS-induced S-AKI mice, renal function was impaired, accompanied by a robust inflammatory response, increased RPS3 protein expression, and enhanced NF-kappaB activation in kidney tissue. Knockdown of RPS3 in HK-2 cells mitigated LPS-induced the inflammatory response and suppressed NF-kappaB activation. However, the effects of RPS3 silencing were partially reversed upon intervention with an NF-kappaB agonist. Collectively, these findings indicate that RPS3 plays a critical role in the inflammatory response of S-AKI via activation of the NF-kappaB signaling pathway, suggesting its potential as a novel therapeutic target for S-AKI. Key words Sepsis-associated acute kidney injury " Inflammatory response " Ribosomal protein S3 " Nuclear factor-kappa B.
Indexed as
Identifiers
41811702PMC13128005What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.